Original document(25 pages)  中文版
    The preparation process of oral Nimoldipine preparation includes the technological steps of: adding polymer carrier hydroxyproply methyl cellulose, polysorbate-80, absorption promoter sodium dodecyl sulfate into ethanol; heating to become transparent; adding low smelting point Nimoldipine while stirring until becoming transparent; quick freezing at -35 to -25 deg.c; adding absorption promoter oleic acid, avical and carboxy methyl amylose sodium to prepare soft material; pelletizing with 18-mesh nylon sieve; drying at 40-50 deg.c; finishing and capsulizing. The Nimoldpine capsule has biological utilization of 94.82% of that of Nimoldipine.
Application Number
申请号
02110531 Application Date
申请日
2002.01.11
Title 名称 Oral Nimoldipine prepn and its prepn process
Publication Number
公开号
1432362 Publication Date
公开日
2003.07.30
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K31/4422,A61P9/10,A61P43/00
Applicant(s) Name
申请人
Hangzhou Saili Medicine Inst. Co., Ltd.
Address 地址 310009
Inventor(s) Name 发明人 Fan Minhua
Attorney & Agent 代理人 wang pengju
More information 更  多  信  息


 Related patents information
Trimebutine maleate tablet and preparing method thereof
Desloratadine dry-mixed suspensoid and preparing method thereof
Dimethyl biguanide sustained release capsule and preparation method thereof
Desloratadine diapersible tablet and its preparation method
Sustained release clarithromycin capsules and its preparation method
Sustained releasing preparation of vilamin C and its preparing method
Oral disintegrants of nimodipine and their preparation
Hydrobromic acid dextro methaphen oral cavity disintegretion tablet and its preparation method
Nimodiping Freeze dried composition and its preparation method
Nicergoline oral cavity disintegration tablet and its preparation method
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.